The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
NCT ID: NCT07143019
Last Updated: 2025-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
214 participants
INTERVENTIONAL
2025-12-31
2032-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
[Trial of device that is not approved or cleared by the U.S. FDA]
NCT07209319
[Trial of device that is not approved or cleared by the U.S. FDA]
NCT01140919
[Trial of device that is not approved or cleared by the U.S. FDA]
NCT07311980
[Trial of device that is not approved or cleared by the U.S. FDA]
NCT07287319
[Trial of device that is not approved or cleared by the U.S. FDA]
NCT07140497
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention/Treatment
Device: Flow diversion using the p48 MW HPC Device: Flow diversion using the p64 MW HPC
Flow diversion
The p48 MW HPC and p64 MW HPC flow modulation device is indicated for use in the treatment of intracranial aneurysms (IAs) arising from a parent vessel with a diameter of ≥2.0mm and ≤5.0 mm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flow diversion
The p48 MW HPC and p64 MW HPC flow modulation device is indicated for use in the treatment of intracranial aneurysms (IAs) arising from a parent vessel with a diameter of ≥2.0mm and ≤5.0 mm.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has a mRS ≤2 before the index procedure
3. Subject has an unruptured or recanalized intracranial aneurysm (IA). The subject may also have a previous ruptured aneurysm, provided rupture of this aneurysm has occurred more than 30 days from the index procedure. The IA must have the following characteristics below:
1. Saccular or fusiform morphology
2. Located in the internal carotid artery and its branches
3. Aneurysm neck ≥4 mm or dome-to-neck ratio \<2
4. Parent vessel diameter ≥2.0mm and ≤5.0mm both distal and proximal to the target IA
4. Subject or subject's legally authorized representative (LAR) has provided written informed consent and has agreed to comply with study procedures.
Exclusion Criteria
2. Any other known IA requiring treatment within 3 months post-procedure
3. Subarachnoid hemorrhage in the past 30 days prior to the index procedure
4. Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular) located at the point of vessel bifurcation
5. Anatomy unsuitable for endovascular procedure due to severe vessel tortuosity or stenosis, or stented ipsilateral carotid artery within 3 months prior to the index procedure
6. Subject with a brain arteriovenous malformation (AVM) or other vascular malformation in the area of the target aneurysm
7. Major surgery in the last 30 days, including endovascular procedures, or is planned in the next 90 days after enrollment date
8. Unstable neurologic deficit (i.e., any worsening of clinical condition in the last 30 days)
9. Known serious sensitivity to radiographic contrast agents that cannot be managed medically
10. Known sensitivity to nickel, titanium metals or their alloys or any other investigational device components
11. Irreversible bleeding disorder and/or signs of active bleeding at subject presentation
12. Known renal failure with a serum creatinine \>2.5 mg/dl (or 220 μmol/l) not on dialysis
13. Contraindication to CT scan, MRI, or angiography
14. Contraindication or known allergies to anticoagulants or antiplatelets (e.g. aspirin, heparin, clopidogrel, prasugrel, or ticagrelor)
15. Known coagulopathy, or an admission International Normalized Ratio \>3.0 without oral anticoagulation therapy, or an admission platelet count of \<100000
16. Has acute life-threatening illness other than the neurological disease (i.e., acute kidney or heart failure) to be treated in this trial
17. Unable to complete the required study follow-ups
18. Evidence of active infection at the time of treatment (e.g., fever, elevated white blood cell count)
19. Participating in another clinical trial that could affect participation or primary outcomes of this study
20. Women currently pregnant or wish to become pregnant during the study or breast feeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Phenox GmbH
INDUSTRY
phenox Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Demetrius Lopes, MD
Role: PRINCIPAL_INVESTIGATOR
Advocate Aurora Research Institute, LLC
Jared Knopman, MD
Role: PRINCIPAL_INVESTIGATOR
The Joan and Sanford I. Weill Medical College of Cornell University
Eytan Raz, MD
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UBNS
Buffalo, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCT-002-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.